AstraZeneca Symposium

AstraZeneca Lunch Symposium

AstraZeneca Australia is part of the global science-led biopharmaceutical company, AstraZeneca. We are engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas – Oncology; BioPharmaceuticals; Vaccine and Immune Therapies; and Rare Disease. We build our own capabilities by collaborating with world-renowned scientists and academic institutions, and partner with like-minded, science-led companies. At AstraZeneca Australia, we have been working to deliver the best value to patients for more than 60 years, and we push the boundaries of science to deliver life-changing medicines.

You’re invited to AstraZeneca’s lunch symposium at Breast Cancer Trials 45th Annual Scientific Meeting. More information will be made available in the near future.

Wednesday 24 July, from 12:00 – 1:30 PM

This symposium will be exploring the topic: ‘What to do after mBC patients progress on CDK4/6i’. You can register for this symposium when completing your conference registration.

Guest Speakers

Carlos Barrios

International Guest Speaker